KLRK1 and neoplasm: In addition, NKG2D ligands are also expressed in tumor blood vessels, myeloid cells, immunosuppressive cells (such as Tregs and MDSCs) and endothelial cells in the tumor microenvironment [36], indicating that NKG2D-CAR could not only target tumors but also other cells in the microenvironment that promote tumor progression.